Neumora Therapeutics, Inc. Common Stock (NMRA) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 6 Buy, 1 Hold, 2 Sell.
The consensus price target is $7.25 (low: $6.00, high: $8.00), representing an upside of 251.9% from the current price $2.06.
Analysts estimate Earnings Per Share (EPS) of $-1.58 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.53 vs est $-1.58 (beat +2.9%). 2025: actual $-1.45 vs est $-1.42 (missed -1.9%). Analyst accuracy: 98%.
NMRA Stock — 12-Month Price Forecast
$7.25
▲ +251.94% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Neumora Therapeutics, Inc. Common Stock, the average price target is $7.25, with a high forecast of $8.00, and a low forecast of $6.00.
The average price target represents a +251.94% change from the last price of $2.06.
Highest Price Target
$8.00
Average Price Target
$7.25
Lowest Price Target
$6.00
NMRA Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Neumora Therapeutics, Inc. Common Stock in the past 3 months
EPS Estimates — NMRA
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.53
vs Est –$1.58
▲ 2.9% off
2025
Actual –$1.45
vs Est –$1.42
▼ 1.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NMRA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
